Protective Efficacy of the Takeda Acellular Pertussis Vaccine Combined With Diphtheria and Tetanus Toxoids Following Household Exposure of Japanese Children

Comparative Efficacy of the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine and Lederle Whole-Cell Component DTP Vaccine in German Children After Household Exposure

“…In most studies, a 28-to 30-day exposure window has been used and this was presumably based on knowledge of the case to case interval during pertussis outbreaks. [2][3][4]6,15,17,19,21,24 However, the frequency distribution of cases by week after exposure as demonstrated by Fine and associates 5 indicates that approximately one-third of cases have their onset Ͼ28 days after exposure. In our trial (Fig 1), 78% of cases occurred within 28 days of exposure and 92% within 42 days of exposure.…”

“…This is evident in recent trials with acellular pertussis vaccines in which household contact analyses has been performed. [15][16][17][18][19][20][21] In addition to our trial, household contact subanalyses were performed in only two other cohort efficacy trials in which laboratory analysis included serologic evidence of infection as well as culture positivity. 17,20,22,23 Of these three trials ours is unique in that detection of possible cases was investigator determined prospectively (telephone calls every 2 weeks) in addition to parent reporting.…”

Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due toBordetella pertussisand OtherBordetellaSubspecies

“…However, in none of the studies were vaccines from a single manufacturer evaluated. Later, one household contact study carried out by multiple investigators evaluated a single vaccine (the Takeda vaccine) (569). In this study, efficacy against all infections was 81% and efficacy against typical infections was 98%.…”

Pertussis vaccines — 1993

“…Use of DTPa there has led to an impressive decrease of reported pertussis cases, but not to the low incidence observed before DTP vaccination was delayed until the age of 2 years. The efficacy of DTPa vaccines to prevent secondary cases after household contacts has been calculated to be around 80%, but figures as high as 98% have been reported [3,23]. Some investigators do not accept these data as sufficient evidence for vaccine efficacy for mainly two reasons.…”